HanAll Biopharma Invests in Interon to Seek Collaboration Op..
- Gains recognition for
contributing to the development of the biopharma industry with expertise in
antibody research and global clinical research capabilities.
- Continues its efforts
to develop innovative medicines by investing over 10% of its annual revenue
into R&D projects.
- Sets a success
model by partnering with global entities to develop treatments in therapeutic
areas including autoimmune, ophthalmology, and neuro immunology through open
collaboration.
HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a
global biopharmaceutical company committed to discovering and developing
innovative medicines for patients, was awarded the 2024 National Industry
Awards in Research and Development.
Organized by the Institute for Industrial
Policy Studies (IPS) and sponsored by the Ministry of Trade, Industry, and
Energy of Korea, the National Industry Awards recognize companies with
significant contributions to national industrial progress.
Renowned for its excellence in R&D, HanAll
was acknowledged for its expertise in antibodies and robust global clinical
research capabilities, driving breakthroughs in the biopharma industry.
"We are deeply honored to receive the 2024
National Industry Award for Research and Development excellence," said Hye
Kyung Ahn, Director of the Bio Research Center, Suwon, Korea.
“This recognition reflects our steadfast
commitment to R&D to develop innovative medicines for patients. We are
dedicated to pushing the boundaries of innovation and providing impactful
solutions to enhance patient lives worldwide," she added.
In line with its steadfast pursuit of
excellence, HanAll invests over 10% of its annual revenue into R&D
projects, ensuring continual progress in its mission to provide innovative
treatments to patients worldwide.
HanAll also established a benchmark for success
by engaging in strategic partnerships with global entities to develop
treatments for conditions with high unmet needs, including autoimmune diseases,
dry eye, and Parkinson’s disease.
Moving into its next 50 years of innovation,
HanAll plans to further expand its efforts to cultivate R&D talents and
promote open collaboration.
About HanAll Biopharma
HanAll Biopharma (KRX: 009420.KS) is a
global biopharmaceutical company with a presence in Korea, the USA, Japan, and
Indonesia with a mission of making meaningful contributions to patients' lives
by introducing innovative, impactful medicines to address severe unmet medical
needs. HanAll has been operating a portfolio of pharmaceutical products in the
areas of endocrine, circulatory, and urologic diseases for over 50 years.
HanAll has also expanded its focus to
immunology, oncology, neurology, and ophthalmology to discover and develop
innovative medicines for patients with diseases for which there are no
effective treatments. Its lead pipeline asset, HL161 (INN: batoclimab), an
anti-FcRn antibody, is being developed in Phase 3 and Phase 2 trials across the
world for the treatment of autoimmune diseases including myasthenia gravis
(MG), thyroid eye disease (TED), chronic inflammatory demyelinating
polyneuropathy (CIDP), and Graves’ disease (GD). Another main asset, HL036
(INN: tanfanercept), a TNF inhibitor protein, is being evaluated in Phase 3
clinical studies in the US and China for the treatment of dry eye disease. For
further information, visit our website and
connect with us on LinkedIn. For
any media inquiries, please contact HanAll PR/IR (pr@hanall.com, ir@hanall.com).
Disclaimer Statement
The contents of this
announcement include statements that are, or may be deemed to be,
"forward-looking statements." These forward-looking statements can be
identified by the use of forward-looking terminology, including the terms
"believes," "estimates," "anticipates,"
"expects," "intends," "may," "will," or
"should," and include statements HANALL (the company, we) makes
concerning its 2024 business and financial outlook and related plans; the
therapeutic potential of its product candidates; the intended results of its
strategy and the company, and its collaboration partners', advancement of, and
anticipated clinical development, data readouts and regulatory milestones and
plans, including the timing of planned clinical trials and expected data
readouts; the design of future clinical trials and the timing and outcome of
regulatory filings and regulatory approvals. By their nature, forward-looking
statements involve risks and uncertainties, and readers are cautioned that any
such forward-looking statements are not guarantees of future performance. The
company's actual results may differ materially from those predicted by the
forward-looking statements. These may include various significant factors, such
as our expectations regarding the inherent uncertainties associated with
competitive developments, preclinical and clinical trial and product
development activities, and regulatory approval requirements. In addition,
performance may be affected by our reliance on collaborations with third
parties, estimating the commercial potential of our product candidates, our
ability to obtain and maintain protection of intellectual property of
technologies and drugs, our limited operating history, and our ability to
obtain additional funding for operations and to complete the development and
commercialization of product candidates. A further list and description of
these risks, uncertainties, and other risks can be found in Korea Stock
Exchange (KRX) filings and reports, including in our most recent annual report
as well as subsequent filings and reports filed by the company with the KRX.
Given these uncertainties, the reader is advised not to place any undue reliance
on such forward-looking statements. These forward-looking statements speak only
as of the date of publication of this document. We undertake no obligation to
publicly or revise the information in this press release, including any
forward-looking statements, except as may be required by Korean law and
regulations.